Tonix Pharmaceuticals Holding Corp. (TNXP)
Nasdaq · Healthcare · Biotechnology
$8.07−9.43%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $138M
- 52-week range
- $8.00 – $24.67
- 52-week change
- −63.21%
- EPS (trailing)
- −$13.06
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $13.1M (+29.85%)
- Net income
- −$124M
- Operating margin
- −959.0%
- Diluted EPS
- −$14.57
- Free cash flow
- −$103M
From the company’s annual report on SEC EDGAR.
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome.
Headquarters: Berkeley Heights, United States · 142 employees · tonixpharma.com